SIR PAUL GIROLAMI TO STAND DOWN

19 June 1994

Glaxo has announced that its chairman, Sir Paul Girolami, has decided to retire and will not be seeking re-election at the company's next annual general meeting. Sir Paul will retire on November 18, 1994, but relinquishes his executive responsibilities as of June 30, coinciding with the end of Glaxo's current financial year.

Although it was known that Sir Paul would be retiring, the June 30 hand-over is over a year earlier than had been expected by industry observers. The company is giving no information as to his successor, other than to say that the appointment of a non-executive chairman will be made in due course.

"It has been a privilege serving our group at the top level for nearly 30 years and a source of pride to see Glaxo become one of the world's leading companies...the markets and the environment in which (these) needs have now to be met are in the course of transformation," said Sir Paul adding "the industry has to respond and it is time for change, and for a change to those who have the task to guide our splendid group to greater heights."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight